Prescribed Trastuzumab? Your HER2-Positive Breast Cancer Diagnosis May Have Been Delayed

Trastuzumab (Herceptin), a revolutionary monoclonal antibody that targets the HER2 protein, has transformed the treatment landscape for HER2-positive breast cancer since its FDA approval in 1998. When your oncologist prescribes this targeted therapy, it indicates your cancer has tested positive for HER2 overexpression, a characteristic found in approximately 15-20% of breast cancers that tends to be more aggressive. While Trastuzumab has dramatically improved outcomes for HER2-positive patients, its necessity often signals a serious diagnosis—particularly when prescribed for later-stage disease (stages III and IV), when five-year survival rates have already decreased substantially from nearly 100% in early stages to approximately 66-87% for stage III and only 29-32% for stage IV. 

If you or a loved one has been prescribed Trastuzumab, it's worth investigating whether earlier detection of your HER2-positive breast cancer might have been possible. In some situations, the need for this medication may indicate a missed or delayed diagnosis that could potentially have been prevented with appropriate medical vigilance.

At the Porter Law Group, we understand the profound impact of a delayed breast cancer diagnosis, particularly for aggressive subtypes like HER2-positive disease. Our specialized medical malpractice attorneys offer no-cost consultations to evaluate your situation and determine whether healthcare providers failed to identify your breast cancer at an earlier, more treatable stage. We are committed to securing accountability when medical negligence fundamentally alters treatment options and survival prospects.

Understanding Trastuzumab and Delayed Diagnosis

Trastuzumab, first approved by the FDA in 1998 for metastatic HER2-positive breast cancer and later expanded to early-stage settings, works by targeting the HER2 receptor protein that is overexpressed in certain breast cancers. This targeted approach blocks growth signals, flags cancer cells for immune system attack, and inhibits cellular repair mechanisms, effectively slowing or stopping cancer progression. While this medication has dramatically improved outcomes for HER2-positive breast cancer patients, it represents a specialized treatment for a particularly aggressive breast cancer subtype.

The prescription of Trastuzumab indicates that your breast cancer has been identified as HER2-positive, requiring this targeted approach. While this medication is used across all stages of HER2-positive disease, the context of its use—particularly in advanced settings—often suggests that the cancer has progressed beyond the earliest, most readily treatable stages. This progression is especially distressing when considering that breast cancer detected at stages 0-I, regardless of subtype, boasts an exceptional five-year survival rate exceeding 99%. At these early stages, treatment approaches, while still requiring Trastuzumab for HER2-positive disease, are typically less intensive, resulting in better outcomes and substantially fewer debilitating side effects.

The attorneys at the Porter Law Group have represented individuals with breast cancer who ultimately required extended treatment and the use of potent drugs like Trastuzumab after healthcare professionals missed critical opportunities for early detection. Through meticulous examination of medical records, our legal team can identify concerning patterns where symptoms were minimized, imaging results were misinterpreted, or standard screening protocols weren't properly implemented. The significant difference between treatment approaches for early-stage disease versus the necessity for more aggressive regimens including Trastuzumab for advanced disease frequently suggests a potential failure in meeting the established standard of care.

Signs of a Delayed Breast Cancer Diagnosis

Medical negligence in breast cancer diagnosis can manifest in various ways, regardless of the cancer's molecular subtype. If you experienced any of the following situations before eventually receiving a diagnosis of HER2-positive breast cancer requiring Trastuzumab, you might have grounds for a medical malpractice claim:

• Healthcare providers downplayed or dismissed early breast symptoms (such as lumps, skin changes, or nipple abnormalities)
• Abnormal findings on mammograms, ultrasounds, or other imaging studies weren't properly investigated
• Appropriate screening based on your specific risk factors and age wasn't recommended
• Referrals to breast specialists were unnecessarily delayed despite concerning findings
• Necessary diagnostic testing wasn't ordered despite persistent symptoms
• Biopsy results were incorrectly interpreted or misreported
• HER2 testing wasn't performed on your initial biopsy sample or was misinterpreted
• Genetic testing wasn't considered despite significant family history of breast cancer

The Porter Law Group breast cancer attorneys excel at identifying these patterns of potential negligence through comprehensive reviews of medical documentation and collaboration with expert witnesses in oncology and diagnostic medicine. We understand that building these cases requires both legal expertise and in-depth medical knowledge regarding breast cancer progression and established standards of care. Contact us today for a free consultation, and view our results to learn more about how we can help you recover compensation. 

How Trastuzumab Is Used in Breast Cancer Treatment

When HER2-positive breast cancer is diagnosed, Trastuzumab becomes an essential component of treatment due to its targeted effectiveness against this specific breast cancer subtype. The medication functions by binding to the HER2 receptor on cancer cells, preventing growth signals, marking the cells for immune system destruction, and inhibiting cellular repair mechanisms.

Trastuzumab is prescribed in several clinical contexts:

• Early-stage and locally advanced breast cancer: As adjuvant (after surgery) or neoadjuvant (before surgery) therapy, typically for up to one year
• Metastatic breast cancer: As first-line or subsequent therapy, alone or with chemotherapy, continued as long as it remains effective and side effects are manageable

The medication is administered intravenously every three weeks, or sometimes weekly, depending on the specific regimen and clinical setting. It is commonly combined with chemotherapy agents such as paclitaxel, docetaxel, carboplatin, or (with careful monitoring) anthracyclines. In some cases, it's used alongside hormone therapy or other HER2-targeted agents like pertuzumab.

A crucial consideration with Trastuzumab is its potential cardiac toxicity, which necessitates careful heart function monitoring before and during treatment. This represents a significant treatment challenge—balancing the proven survival benefits against the risk of heart dysfunction, particularly when combined with other cardiotoxic treatments.

While Trastuzumab has revolutionized HER2-positive breast cancer treatment, reducing recurrence by 34% and breast cancer mortality by 33% compared to chemotherapy alone in early-stage disease, its use—particularly in advanced settings—often indicates that the cancer has progressed beyond the earliest, most treatable stages. In many instances, this progression might have been prevented with timely detection, allowing for earlier intervention with this highly effective targeted therapy.

Serious Risks and Side Effects

Trastuzumab's therapeutic benefits come with significant potential toxicities that require careful monitoring and management. These side effects are particularly concerning when considering they might have been minimized with earlier diagnosis and treatment at an earlier disease stage. Major side effects include:

1. Cardiotoxicity: The most significant risk of Trastuzumab is heart dysfunction, including congestive heart failure and decreased left ventricular ejection fraction. This cardiac impact occurs in approximately 3-7% of patients receiving Trastuzumab alone, 13% when combined with paclitaxel, and up to 27% when used with anthracycline/cyclophosphamide regimens. Regular cardiac monitoring is essential throughout treatment.
2. Infusion Reactions: Patients may experience reactions during administration, particularly with the first dose, including fever, chills, nausea, vomiting, pain, rigors, headache, dizziness, and rash. While most reactions are mild to moderate, severe reactions occur in approximately 0.3% of patients.
3. Pulmonary Toxicity: Though rare, Trastuzumab can cause serious lung problems, including interstitial pneumonitis and acute respiratory distress syndrome. Symptoms may include shortness of breath, cough, fatigue, and fluid in the lungs, requiring prompt medical attention.

Common side effects experienced by many patients include:

• Fever and chills
• Nausea and vomiting
• Diarrhea
• Significant fatigue
• Headache
• Insomnia
• Mild increase in infection risk when combined with chemotherapy

At the Porter Law Group, we believe these side effects represent an especially unjust burden when they result from preventable diagnostic delays. When healthcare providers miss opportunities for early detection of HER2-positive breast cancer, patients face not only reduced survival probabilities but must also endure potentially more intensive treatment regimens and associated toxicities that might have been minimized with proper medical attention.

Legal Options Following a Delayed Diagnosis

When a HER2-positive breast cancer diagnosis is delayed, potentially necessitating more aggressive or extended treatments with Trastuzumab at later disease stages, patients may have legitimate grounds for a medical malpractice claim. Successfully pursuing these cases requires establishing four fundamental elements:

1. Duty of Care: The healthcare provider had a professional obligation to deliver care according to accepted medical standards for breast cancer screening, diagnosis, and follow-up.
2. Breach of Standard: The provider failed to fulfill this standard through either action or inaction (such as misinterpreting imaging results, dismissing reported symptoms, failing to order appropriate tests, or not performing proper HER2 testing).
3. Causation: This failure directly resulted in a delayed diagnosis, allowing the cancer to advance to a more serious stage requiring more aggressive treatment approaches.
4. Damages: The patient suffered measurable harm as a consequence, including decreased survival probability, requirement for more intensive treatment protocols, additional medical expenses, lost wages, pain and suffering, and diminished quality of life.

The Porter Law Group attorneys construct these cases through exhaustive investigation, including:

• Thorough examination of all relevant medical records
• Consultation with expert oncologists who can establish how earlier diagnosis would have altered treatment approaches and prognosis
• Detailed analysis of imaging studies, pathology reports, and HER2 testing results
• Comprehensive evaluation of the medical timeline to identify critical missed opportunities
• Assessment of specific breaches in the standard of care at each stage

Our firm has successfully advocated for numerous clients in delayed breast cancer diagnosis cases throughout New York State. We understand the complex medical evidence required to demonstrate how earlier intervention would have significantly altered both treatment courses and likely outcomes. While specific results cannot be guaranteed, our established record demonstrates our commitment to securing justice for victims of medical negligence.

Legal History of Trastuzumab

Trastuzumab has a well-documented medical and legal history that can strengthen potential malpractice claims related to delayed breast cancer diagnosis. Since its initial FDA approval in 1998 for metastatic HER2-positive breast cancer, with later expansion to adjuvant and neoadjuvant settings, this medication has transformed the standard of care for HER2-positive breast cancer.

The medication is included in all major breast cancer treatment guidelines for HER2-positive disease, with clear protocols for appropriate patient selection, administration, and monitoring. Multiple biosimilar versions have been approved and are in use worldwide, further establishing its central role in breast cancer treatment.

The medical community has established clear guidelines regarding breast cancer screening, diagnosis, HER2 testing, and treatment protocols. When a patient ultimately requires Trastuzumab following missed opportunities for earlier diagnosis, these established guidelines can serve as compelling evidence of deviations from the standard of care.

Additionally, the extensive research demonstrating Trastuzumab's significant survival benefits—reducing recurrence by approximately one-third in early-stage disease—underscores the critical importance of timely diagnosis and treatment initiation for HER2-positive breast cancer. Delays in diagnosis that result in more advanced disease at presentation represent significant lost opportunities for optimal treatment outcomes.

Why Choose the Porter Law Group

The lawyers at the Porter Law Group have decades of experience representing individuals and families whose lives have been devastated by catastrophic injuries. We have obtained some of the largest settlements and verdicts in courts throughout the State of New York. We are a state-wide firm that handles cases with a hometown feel.

Our clients come to us looking for guidance and answers. With seasoned trial lawyers, the Porter Law Group has the resources necessary to help you navigate the most complex cases, against goliath insurance companies that will stop at nothing to prevent you from receiving the compensation you deserve.

You only get one chance to hire the best lawyer for you and your family. Hire the lawyers most recommended by former clients and local attorneys, and the firm that obtains superior results.

When you or a loved one's life has been devastated by a serious personal injury in New York, don't hire a lawyer without calling the Porter Law Group to learn why so many of our clients are thankful they trusted us with their case in their time of need.

Injured by Medical Malpractice in New York?

Reach out to our experienced team for a free consultation and explore your options for compensation.

Contact Us

When to Contact a Cancer Misdiagnosis Attorney

If you or a loved one has received a diagnosis of HER2-positive breast cancer requiring treatment with Trastuzumab, consider consulting with our medical malpractice attorneys if:

• You previously reported breast symptoms that healthcare providers dismissed or minimized
• Abnormal findings appeared on mammograms or other imaging studies that weren't appropriately addressed
• You needed to persistently advocate before receiving proper diagnostic evaluation
• Unusual delays occurred between your initial concerns and receiving a definitive diagnosis
• Medical professionals assured you not to worry about symptoms that later proved to be cancer
• Your healthcare provider failed to recommend appropriate screening protocols based on your age and risk profile
• Upon switching providers, a new doctor immediately identified concerning findings that previous providers overlooked
• Your pathology results or HER2 testing were incorrectly interpreted, resulting in delayed treatment

The earlier you contact our firm, the better positioned we'll be to preserve critical evidence and begin constructing your case.

Consult with a Breast Cancer Misdiagnosis Lawyer Today

If you or someone you love is now facing HER2-positive breast cancer requiring Trastuzumab treatment following what you believe might have been a preventable diagnostic delay, the Porter Law Group stands ready to assist. Our experienced medical malpractice attorneys understand the profound impact of delayed cancer diagnosis and are committed to helping you secure the compensation you deserve.

We handle all medical malpractice cases on a contingency fee basis, meaning you pay absolutely nothing unless we recover compensation on your behalf. This arrangement allows you to concentrate on your health and treatment while we vigorously pursue justice for you.

The window for action is limited by New York's statute of limitations for medical malpractice claims. Don't postpone seeking the legal guidance you need. Contact the Porter Law Group today at 833-PORTER9 or info@porterlawteam.com to schedule your free, confidential consultation.

Together, we can hold negligent healthcare providers accountable and secure the resources necessary for your ongoing treatment, lost income, and the pain and suffering caused by unnecessary progression of your breast cancer.

DISCLAIMER: This article is not intended to provide medical advice. The medical information provided is for general informational purposes only. Always consult with qualified healthcare professionals regarding any medical conditions or treatments. This content does not establish an attorney-client relationship, and prior results do not guarantee a similar outcome. Every case is unique and outcomes depend on the specific facts and circumstances involved.